Hyloris Sets Out IPO Terms

Value-Added Medicines Specialist Eyes US 505(b)(2) Opportunities

 
• By Dave Wallace

Value-added medicines specialist Hyloris Pharmaceuticals has set out the financial terms for its IPO, aimed at providing funds to pursue US 505(b)(2) opportunities.

Euro
Hyloris has set out financial terms for its IPO • Source: Shutterstock

More from Strategy

More from Business